167 related articles for article (PubMed ID: 38378036)
21. PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program.
Li L; Sun R; Miao Y; Tran T; Adams L; Roscoe N; Xu B; Manyam GC; Tan X; Zhang H; Xiao M; Tzankov A; Visco C; Dybkaer K; Bhagat G; Tam W; Hsi ED; van Krieken JH; You H; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Piris MA; Zhang M; Winter JN; Medeiros LJ; Rassidakis GZ; Vaupel CA; Li Y; Dakappagari N; Xu-Monette ZY; Young KH
Mod Pathol; 2019 Jun; 32(6):741-754. PubMed ID: 30666052
[TBL] [Abstract][Full Text] [Related]
22. Understanding Immune Evasion and Therapeutic Targeting Associated with PD-1/PD-L1 Pathway in Diffuse Large B-cell Lymphoma.
Song MK; Park BB; Uhm J
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30884772
[TBL] [Abstract][Full Text] [Related]
23. Clinicopathological features of programmed cell death-1 and programmed cell death-ligand-1 expression in the tumor cells and tumor microenvironment of angioimmunoblastic T cell lymphoma and peripheral T cell lymphoma not otherwise specified.
Kim S; Kwon D; Koh J; Nam SJ; Kim YA; Kim TM; Kim CW; Jeon YK
Virchows Arch; 2020 Jul; 477(1):131-142. PubMed ID: 32170448
[TBL] [Abstract][Full Text] [Related]
24. Prognostic impact of PD-L1 expression in primary gastric and intestinal diffuse large B-cell lymphoma.
Ishikawa E; Nakamura M; Shimada K; Tanaka T; Satou A; Kohno K; Sakakibara A; Furukawa K; Yamamura T; Miyahara R; Nakamura S; Kato S; Fujishiro M
J Gastroenterol; 2020 Jan; 55(1):39-50. PubMed ID: 31493237
[TBL] [Abstract][Full Text] [Related]
25. Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies.
Xu-Monette ZY; Li J; Xia Y; Crossley B; Bremel RD; Miao Y; Xiao M; Snyder T; Manyam GC; Tan X; Zhang H; Visco C; Tzankov A; Dybkaer K; Bhagat G; Tam W; You H; Hsi ED; van Krieken JH; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Piris MA; Winter JN; Medeiros JT; Xu B; Li Y; Kirsch I; Young KH
J Immunother Cancer; 2019 Oct; 7(1):272. PubMed ID: 31640780
[TBL] [Abstract][Full Text] [Related]
26. PD-L1 expression is low in large B-cell lymphoma with MYC or double-hit translocation.
Elbaek MV; Pedersen MØ; Breinholt MF; Reddy A; Love C; Clasen-Linde E; Knudsen H; Nielsen SL; Gang AO; Høgdall E; Dave S; Nørgaard P
Hematol Oncol; 2019 Oct; 37(4):375-382. PubMed ID: 31408531
[TBL] [Abstract][Full Text] [Related]
27. Clinical Significance of
Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
[No Abstract] [Full Text] [Related]
28. Prognostic implications of the tumor immune microenvironment and immune checkpoint pathway in primary central nervous system diffuse large B-cell lymphoma in the North Indian population.
Parkhi M; Chatterjee D; Bal A; Vias P; Yadav BS; Prakash G; Gupta SK; Radotra BD
APMIS; 2022 Feb; 130(2):82-94. PubMed ID: 34862664
[TBL] [Abstract][Full Text] [Related]
29. CD3+/CD8+ T-cell density and tumoral PD-L1 predict survival irrespective of rituximab treatment in Chinese diffuse large B-cell lymphoma patients.
Shi Y; Deng L; Song Y; Lin D; Lai Y; Zhou L; Yang L; Li X
Int J Hematol; 2018 Sep; 108(3):254-266. PubMed ID: 29748856
[TBL] [Abstract][Full Text] [Related]
30. PD-L1 and PD-L2 Are Differentially Expressed by Macrophages or Tumor Cells in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.
Menguy S; Prochazkova-Carlotti M; Beylot-Barry M; Saltel F; Vergier B; Merlio JP; Pham-Ledard A
Am J Surg Pathol; 2018 Mar; 42(3):326-334. PubMed ID: 29112015
[TBL] [Abstract][Full Text] [Related]
31. Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas.
Kwon D; Kim S; Kim PJ; Go H; Nam SJ; Paik JH; Kim YA; Kim TM; Heo DS; Kim CW; Jeon YK
Histopathology; 2016 Jun; 68(7):1079-89. PubMed ID: 26426431
[TBL] [Abstract][Full Text] [Related]
32. Expression of Tryptophan Metabolism Enzymes in Patients with Diffuse Large B-cell Lymphoma and NK/T-cell Lymphoma.
Guo D; Wang Y; Wu X; Gao Y; Wang A; Zhang Z; Zhao K; Wang X; Liu M; Zhang Y; Li M; Chen R; Sun J; Zhang Y
Cancer Med; 2023 Jun; 12(11):12139-12148. PubMed ID: 37148546
[TBL] [Abstract][Full Text] [Related]
33. Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas.
Alame M; Pirel M; Costes-Martineau V; Bauchet L; Fabbro M; Tourneret A; De Oliveira L; Durand L; Roger P; Gonzalez S; Cacheux V; Rigau V; Szablewski V
Virchows Arch; 2020 Jun; 476(6):891-902. PubMed ID: 31811434
[TBL] [Abstract][Full Text] [Related]
34. Expression of PD-L1 and YWHAZ in Patients with Diffuse Large B Cell Lymphoma: A Possible Association with the Prognosis of Lymphoma.
Yan S; Shang Q; Fan Z; Yang Y; Liu Y; Gao H; Chen K; Liang F; Li X; Zhang Q; Yan H
J Immunol Res; 2022; 2022():5633096. PubMed ID: 36213322
[TBL] [Abstract][Full Text] [Related]
35. The prognostic and clinicopathological significance of PD-L1 expression in patients with diffuse large B-cell lymphoma: a meta-analysis.
Qiu L; Zheng H; Zhao X
BMC Cancer; 2019 Mar; 19(1):273. PubMed ID: 30917792
[TBL] [Abstract][Full Text] [Related]
36. Clinicopathological Study of PD-1/PD-L1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) with Emphasis on Large B-Cell Richter Transformation.
Masoud R; Eladl AE; El-Ashwah S; Abbas A; Kandil W
Asian Pac J Cancer Prev; 2023 Dec; 24(12):4243-4252. PubMed ID: 38156860
[TBL] [Abstract][Full Text] [Related]
37. Soluble programmed cell death protein 1 (sPD-1) and the soluble programmed cell death ligands 1 and 2 (sPD-L1 and sPD-L2) in lymphoid malignancies.
Mortensen JB; Monrad I; Enemark MB; Ludvigsen M; Kamper P; Bjerre M; d'Amore F
Eur J Haematol; 2021 Jul; 107(1):81-91. PubMed ID: 33721375
[TBL] [Abstract][Full Text] [Related]
38. [Expression of PD-L1 and PD-1 in Pathological Tissue of Patients Newly Diagnosed with Diffuse Large B-Cell Lymphoma].
Bao F; Ke XY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Jun; 30(3):778-783. PubMed ID: 35680805
[TBL] [Abstract][Full Text] [Related]
39. Correlation between PD-1 and sPD-L1 expression levels in peripheral blood of DLBCL patients and their clinicopathological characteristics.
Wang L; Cao C; Qiu J; Zhang J; He Q; Song L; Xie L; Ma J
Cell Mol Biol (Noisy-le-grand); 2024 Feb; 70(2):44-50. PubMed ID: 38430041
[TBL] [Abstract][Full Text] [Related]
40. [Programmed cell death-1 inhibitor combined with rituximab in refractory or relapsed diffuse large B-cell lymphoma: a preliminary efficacy and safety analysis].
Qin Y; Zhao FY; Zhou Y; Jiang SY; Yang S; Shi YK
Zhonghua Zhong Liu Za Zhi; 2020 Dec; 42(12):1034-1039. PubMed ID: 33342160
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]